Clinical Trials Logo

B Cell Leukemia clinical trials

View clinical trials related to B Cell Leukemia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05932173 Recruiting - B-Cell Lymphoma Clinical Trials

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

Start date: July 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+ refractory/relapsed B-Cell malignancies.

NCT ID: NCT05487651 Recruiting - B-cell Lymphoma Clinical Trials

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

ANCHOR2
Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

NCT ID: NCT05442515 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Start date: December 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL. Eligibility: People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy. Design: Participants will be screened. This will include: Physical exam Blood and urine tests Tests of their lung and heart function Imaging scans Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone. Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord. Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells. Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment. Participants will be admitted to the hospital. Their own modified T cells will be returned to their body. Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....

NCT ID: NCT04747093 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Induced-T Cell Like NK Cells for B Cell Malignancies

Start date: January 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.

NCT ID: NCT04516551 Recruiting - B Cell Leukemia Clinical Trials

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Start date: November 20, 2020
Phase: Phase 1
Study type: Interventional

The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation. Nowadays there is no effective way to salvage patients in such conditions. T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.

NCT ID: NCT04156243 Recruiting - B Cell Lymphoma Clinical Trials

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Start date: February 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04156178 Recruiting - B Cell Lymphoma Clinical Trials

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Start date: August 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04016129 Recruiting - B-cell Leukemia Clinical Trials

CAR-T Immunotherapy Targeting CD19- ALL

Start date: July 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

NCT ID: NCT03881774 Recruiting - B Cell Lymphoma Clinical Trials

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells

NCT ID: NCT03463928 Recruiting - B Cell Leukemia Clinical Trials

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

Start date: October 8, 2017
Phase: Phase 1
Study type: Interventional

Allogenic hematopoietic stem cell transplant (Allo-HSCT) is routinely used for treatment of aggressive hematological malignancies. The biological foundation of allo-HSCT is the graft-versus-leukemia (GVL) effect, which is primarily mediated by donor T cells present in the graft and is able to eradicate malignant B cells either CD19+ or CD19-. Relapse following an allo-HSCT remains a major challenge in the treatment of B-ALL. CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells. Co-infusion of donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells and donor-derived-HSCT has the potential to combine the CAR-T cell mediated targeted elimination of CD19 expressing B cells with GVL effect, which could have clear advantages in reducing the risk of relapse and the evolution of CD19− escape variants or clonally related malignancies in other lineages. Therefore, a complete and durable tumor responses induced by this immunotherapy could be expected.